PHARMACEUTICAL COMBINATION FOR THE PROPHYLAXIS OR TREATMENT OF CARDIOVASCULAR, CARDIOPULMONARY, PULMONARY OR RENAL DISEASES
The use of the angiotensin II receptor antagonist telmisartan (I) (or its salt) and the 3-hydroxy-2-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin (II) is claimed in the production of medicaments (A) for the treatment or prophylaxis of cardiovascular, cardiopulmonary or renal di...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English French German |
Published |
26.10.2005
|
Edition | 7 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The use of the angiotensin II receptor antagonist telmisartan (I) (or its salt) and the 3-hydroxy-2-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin (II) is claimed in the production of medicaments (A) for the treatment or prophylaxis of cardiovascular, cardiopulmonary or renal diseases. Independent claims are included for corresponding treatment methods and pharmaceutical compositions. ACTIVITY : Cardiant; Vasotropic; Hepatotropic; Hypotensive; Antilipemic; Antiarteriosclerotic; Antiasthmatic; Antiinflammatory; Antidiabetic; Cerebroprotective; Antianginal; Cytostatic; Antibacterial; Immunosuppressive; Vulnerary; Osteopathic; Neuroprotective; Nootropic. MECHANISM OF ACTION : Angiotensin II receptor antagonist; HMG-CoA reductase inhibitor; Peroxisome proliferator activated receptor-gamma (PPAR-gamma ) regulating gene expression inducer; Matrix metalloproteinase MMP-9 expression controller; Cytokine CD40L antagonist. |
---|---|
Bibliography: | Application Number: EP20040701918 |